Bangladesh Medical Device Registration: Paper Submission with No Electronic Portal

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

As of October 27, 2026, Bangladesh medical device registration still has no electronic submission portal; all submissions are made on paper. Applicants must submit paper-printed and bound documents to DGDA, and officials verify the physical documents. This single fact directly determines three major aspects of any Bangladesh project: the logistics budget, the embassy attestation schedule, and the custody responsibility for original documents. Each of these three is a cost line that electronic-submission markets simply do not have, and each needs an owner and a date in the project plan from day one.

  • No online submission system: “There is no online submission system yet. Everything is manual.” — interview with a practising professional in 2026 (practical estimate).
  • Paper-printed documents must be submitted: “You must submit a hard-copy printed document to the authority, and they check the physical documents.” — same interview.
  • A future online launch is possible: the government may in the near term advance online submission, but the current process is a document-based paper flow — same interview.
  • Sampling and verification: sampling follows the prescribed procedure; where necessary DGDA may adopt other verification measures, per §4.9 of the DGDA Medical Device Registration Guidelines.
  • Conflict with claims that an electronic registration system is already in place: some sources state that Bangladesh has already rolled out an electronic registration system — not adopted (see the dedicated analysis article).

2. Legal basis

The table below consolidates the basis for the paper-submission finding. The core statements — no online portal, hard-copy submission, physical verification — come from a 2026 interview with a practising professional and are classified as a practical estimate. The sampling verification provision is anchored in §4.9 of the Guidelines. Conflicting claims about an existing electronic system are explicitly recorded as not adopted, with the reasoning set out in the dedicated analysis article.

No online submission system“There is no online submission system yet. Everything is manual.”2026 interview with a practising professional (practical estimate)
Paper-printed documents must be submitted“You must submit a hard-copy printed document to the authority, and they check the physical documents.”Same interview
Online launch may come in futureThe government may in the near term advance online submission, but the current process is a document-based paper flowSame interview
Sampling and verificationSampling follows the prescribed procedure; where necessary DGDA may adopt other verification measuresDGDA Medical Device Registration Guidelines §4.9 (Guidelines provision)
Conflict with claims that an electronic registration system is already in placeSome sources state that Bangladesh has already rolled out an electronic registration systemNot adopted (see the dedicated analysis article)

3. Expert insights

Insight one: paper submission makes geographic distance a compliance variable again. Online submission drives the cost of filing to nearly zero; paper submission requires someone to physically place the dossier in the hands of DGDA. This changes the selection of a local partner from a credentials question into an execution question — without a reliable local team, even the most complete electronic documentation cannot become a filed dossier. The quality of the on-the-ground presence, its familiarity with the DGDA counter routines, and its ability to respond same-day to filing queries now sit on the critical path of the project in a way that purely digital markets never demand.

Insight two: paper submission amplifies the value of originals. In an electronic system, a scan is usually sufficient; in a paper system, officials verify the physical object. This explains why the final review stage explicitly requires the original CFS and the original empty packaging (see the dedicated article), and why embassy attestation cannot be skipped (see the attestation article). The physical nature of the process is not an administrative preference to be tolerated; it is the operating logic of the entire system, and every document strategy should be designed around it from the start. A strategy that works in markets with e-filing — building the dossier digitally and converting to paper at the last moment — imports unnecessary risk here, because the conversion step itself becomes the point where formatting and pagination errors are born.

Insight three: the cost of changes in a paper process is extremely high. In an online system, changing a field takes ten seconds; in a paper dossier, changing a page means reprinting, rebinding and resubmitting. This amplifies the value of a dossier internal review — we require every Bangladesh dossier to complete a full internal review before binding, because the cost of a change after binding is a hundred times the cost before it. Companies that treat the dossier as a living document and plan to fix issues during review are importing a software mindset into a print-shop reality, and the schedule pays for it.

4. Practical recommendations

  • Manage the Bangladesh dossier as a print product: unified formatting, unified page numbering, unified binding sequence, and a dossier table of contents output as the submission cover sheet.
  • Complete three rounds of internal review before binding: regulatory review, technical review, and formatting review.
  • Advise clients to retain one complete copy set for archival — paper submission leaves no system trail, and if DGDA requests supplementary documents, a company without its own copy must re-produce the entire document set.
  • Arrange for a Bangladesh local team to be responsible for the physical submission and for any same-day responses required at the DGDA counter.
  • List the launch of a DGDA electronic submission system as an annual regulatory monitoring item, so the paper assumption is revisited on a fixed cadence.

5. Verification checklist

  • □ The submission method has been confirmed as paper (no electronic portal as of 2026-10-27)
  • □ A Bangladesh local team has been arranged to handle the physical submission
  • □ The dossier has completed the three pre-binding internal reviews (regulatory, technical, formatting)
  • □ A dossier table of contents and page numbering have been produced
  • □ One complete copy set has been archived for supplementary document requests
  • □ The launch of DGDA electronic submission has been listed as an annual regulatory monitoring item

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Bangladesh. Our team prepares dossiers to DGDA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Regulatory information verified as of October 27, 2026.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail